Triple
T9807104
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | MabThera |
E238179
|
entity |
| Predicate | isMarketedAs |
P5087
|
FINISHED |
| Object |
MabThera SC for subcutaneous formulation
MabThera SC for subcutaneous formulation is a subcutaneously administered version of the monoclonal antibody rituximab, used primarily in the treatment of certain blood cancers and autoimmune diseases.
|
E822403
|
NE FINISHED |
Provenance (5 batches)
| Stage | Batch ID | Job type | Status |
|---|---|---|---|
| creating | batch_69ca84defac48190abc1148804f184c1 |
elicitation | completed |
| NER | batch_69cdab7cb9588190953a063cb7b9e29e |
ner | completed |
| NED1 | batch_69d1cc57119881909616d835def02fc9 |
ned_source_triple | completed |
| NED2 | batch_69d1cd8fcf488190bc72a99e81fb618b |
ned_description | completed |
| NEDg | batch_69d1cd137b30819089356b9fbc265d17 |
nedg | completed |
Created at: March 30, 2026, 8:29 p.m.